Subscribe To Our Newsletter
Subscribe To Our Newsletter
Strides Pharma, Inc. has agreed to a class action settlement of at least $750,000 to resolve a lawsuit, Painter v. Strides Pharma, Inc., alleging the company manufactured and sold prescription testosterone gel contaminated with benzene, a known carcinogen.
Strides Pharma, Inc. has agreed to a class action lawsuit settlement of at least $750,000 to resolve allegations that the company manufactured and distributed prescription testosterone gel contaminated with benzene, a known human carcinogen. The legal deal provides direct financial reimbursement to an estimated 95,000 consumers nationwide who purchased the affected medication for personal or household use.
The nationwide legal action, titled Painter v. Strides Pharma, Inc., was filed in the U.S. District Court for the Southern District of New York under case number 7:25-CV-4189. The consumer protection lawsuit alleges that the pharmaceutical manufacturer failed to meet mandatory federal and state drug safety standards. Specifically, the plaintiffs claim that Strides Pharma utilized a raw ingredient called Carbomer 940 to manufacture its product. According to the lawsuit, this thickener is heavily produced using benzene, causing the final topical gel to contain levels of the toxic chemical that exceed acceptable regulatory limits.
The plaintiffs argue that everyday people purchased this medication to safely treat low testosterone levels, transition their gender, or manage hormone replacement therapies. Instead of receiving a pure, medically sound pharmaceutical product, consumers were allegedly exposed to hidden chemical dangers. For decades, consumer advocates and health institutions have fought to keep dangerous toxins out of everyday medical supplies. While Strides Pharma has firmly denied all of the legal allegations and refuses to admit any liability or wrongdoing, the corporation chose to establish this settlement fund to avoid the ongoing financial burdens and unpredictable risks of an extended courtroom trial.
Benzene is an industrial chemical and a designated human carcinogen that has been heavily regulated by federal agencies for more than 40 years. Medical professionals and global health organizations have established that there is no safe or acceptable baseline level of benzene in prescription medications, especially products like topical gels that are applied directly to the skin and absorbed into the human body. Because the skin acts as an active gateway, chemical contaminants can easily breach the body’s natural defense systems.
Medical research shows that prolonged or repetitive exposure to benzene can cause severe long-term health complications, including immune system suppression, liver damage, kidney issues, and severe bone marrow and blood disorders. Most notably, benzene exposure is directly linked to the development of blood-related cancers, such as leukemia. It is important to clarify that this economic loss settlement is designed to compensate you for the money you spent purchasing the medication; it does not settle or waive any separate legal claims for personal injuries or wrongful death that a consumer may choose to pursue independently.
The $750,000 settlement fund is structured as a non-reversionary fund, meaning that every single dollar in the pool must be distributed to consumers, and no remaining cash will be returned to Strides Pharma. The financial relief is broken down into specific percentage tiers depending entirely on the calendar year you filled your prescription, reflecting the varying costs and levels of exposure across the class window.
The court-approved refund tiers are outlined as follows:
Purchases between January 1, 2025, and July 31, 2025: You may be eligible to receive a full 100% reimbursement of all out-of-pocket payments made for each individual prescription.
Purchases between January 1, 2024, and December 31, 2024: You may be eligible to receive a 75% reimbursement of your out-of-pocket costs for each prescription.
Purchases between June 1, 2022, and December 31, 2023: You may be eligible to receive a 40% reimbursement of your out-of-pocket costs for each prescription.
Minimal or Zero Out-of-Pocket Costs: If your insurance fully covered the product or your out-of-pocket expense was less than $3.50, you can receive a baseline recovery of $3.50 per prescription, subject to the corresponding percentage reductions based on the year of purchase.
One unique and consumer-friendly element of this specific settlement is that individual payouts are not strictly capped at the initial percentage levels. If the total number of valid claims filed by everyday people by the official deadline does not exhaust the minimum $750,000 fund, the remaining cash balance will be distributed to participating class members on a pro-rata basis. This means your individual check could ultimately be higher than the base tier numbers as the system distributes the remaining cash proportionally.
Furthermore, you do not have to worry about your personal cash share being eaten away by hidden administrative costs. Strides Pharma has explicitly agreed to pay for all third-party settlement administration expenses, legal notice distributions, court-approved attorneys’ fees, and representative service awards entirely separate from the $750,000 consumer fund. This intentional setup ensures that the money allocated for class members remains completely untouched and is delivered straight into the hands of the consumers who paid for the product.
Beyond the immediate financial relief provided to the consumer class, this litigation has forced Strides Pharma to implement significant structural changes to its drug manufacturing operations. To resolve the lawsuit, the pharmaceutical manufacturer was required to completely reformulate its topical testosterone gel to address the underlying Carbomer 940 issue and eliminate the chemical risk factor entirely from its current supply lines.
Additionally, the company has legally committed to a strict program of continuous chemical testing. This ongoing monitoring protocol ensures that future batches of the product remain completely free from benzene contamination before they are shipped to commercial pharmacies, wholesalers, or distributors. This means your action as a consumer does more than secure a personal refund—it actively helps clean up the pharmaceutical supply chain, ensuring that future patients can access their necessary hormone therapies without fearing hidden toxic ingredients.
If you are wondering whether you have a stake in this consumer victory, the eligibility parameters have been formally defined by the court. You may be eligible to receive a cash payment from this settlement if you are a natural person in the United States who purchased prescription Strides testosterone gel for personal or household use. The legal parameters specifically apply to medications carrying the National Drug Code (NDC) numbers 64380-0151-02 (2.5-gram packets) or 64380-0152-02 (5-gram packets).
The qualified timeframe spans a multi-year window. Your purchases must have occurred between the dates of June 1, 2022, and July 31, 2025. To successfully claim your refund, you will need to provide valid proof of purchase along with your claim form. This required proof can be easily established through reliable personal records, including pharmacy dispensing logs, insurance explanation of benefits (EOB) statements, or standard retail receipts that show the specific drug name, purchase date, and amount paid.
To claim your piece of the settlement fund, you must take active steps to complete and submit a valid claim form. The official, court-approved portal has been established at StridesGelSettlement.com. Through this secure portal, you can choose to complete your claim form entirely online or download a personalized paper version to print out and return to the settlement administrator via traditional mail.
Please keep these critical calendar dates in mind to ensure you don’t lose out on your consumer rights:
Filing Deadline: All completed claim forms must be submitted online or postmarked by September 16, 2026. If you miss this date, you will lose your right to a cash refund.
Final Approval Hearing: The presiding judge has scheduled the final approval hearing for November 19, 2026, to review the ultimate fairness of the deal.
Distribution Window: Cash reimbursements will begin rolling out to approved claimants after the court grants final approval and any subsequent legal appeals are fully resolved.
New cases and investigations, settlement deadlines, and news straight to your inbox.
